Boston Scientific Corporation (BSX) Shares Bought by Nordea Investment Management AB

Nordea Investment Management AB lifted its stake in Boston Scientific Corporation (NYSE:BSX) by 10.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 81,906 shares of the medical equipment provider’s stock after purchasing an additional 7,484 shares during the period. Nordea Investment Management AB’s holdings in Boston Scientific were worth $2,389,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of the company. Comerica Securities Inc. lifted its position in shares of Boston Scientific by 0.9% in the 2nd quarter. Comerica Securities Inc. now owns 11,478 shares of the medical equipment provider’s stock worth $318,000 after purchasing an additional 99 shares during the period. ETRADE Capital Management LLC lifted its position in shares of Boston Scientific by 1.7% in the 2nd quarter. ETRADE Capital Management LLC now owns 10,079 shares of the medical equipment provider’s stock worth $279,000 after purchasing an additional 171 shares during the period. Krilogy Financial LLC lifted its position in shares of Boston Scientific by 5.9% in the 2nd quarter. Krilogy Financial LLC now owns 7,680 shares of the medical equipment provider’s stock worth $213,000 after purchasing an additional 430 shares during the period. Wetherby Asset Management Inc. lifted its position in shares of Boston Scientific by 3.9% in the 2nd quarter. Wetherby Asset Management Inc. now owns 13,788 shares of the medical equipment provider’s stock worth $382,000 after purchasing an additional 523 shares during the period. Finally, Greenwood Capital Associates LLC lifted its position in shares of Boston Scientific by 1.1% in the 2nd quarter. Greenwood Capital Associates LLC now owns 53,330 shares of the medical equipment provider’s stock worth $1,478,000 after purchasing an additional 564 shares during the period. 90.57% of the stock is owned by hedge funds and other institutional investors.

Boston Scientific Corporation (NYSE BSX) opened at $24.94 on Wednesday. Boston Scientific Corporation has a 12-month low of $20.36 and a 12-month high of $29.93. The stock has a market cap of $34,192.58, a PE ratio of 20.41, a P/E/G ratio of 1.92 and a beta of 0.96. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.50 and a current ratio of 0.72.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Thursday, October 26th. The medical equipment provider reported $0.31 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.31. Boston Scientific had a net margin of 9.55% and a return on equity of 23.60%. The company had revenue of $2.22 billion during the quarter, compared to analysts’ expectations of $2.21 billion. During the same period last year, the company posted $0.27 EPS. Boston Scientific’s revenue was up 5.6% on a year-over-year basis. equities analysts anticipate that Boston Scientific Corporation will post 1.25 earnings per share for the current year.

BSX has been the subject of several research analyst reports. Oppenheimer reaffirmed a “hold” rating on shares of Boston Scientific in a research report on Wednesday, August 9th. BidaskClub raised shares of Boston Scientific from a “sell” rating to a “hold” rating in a research report on Saturday, August 19th. Royal Bank Of Canada reaffirmed a “buy” rating and issued a $31.00 target price on shares of Boston Scientific in a research report on Friday, September 1st. Jefferies Group reaffirmed a “hold” rating on shares of Boston Scientific in a research report on Thursday, September 7th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and issued a $32.00 target price on shares of Boston Scientific in a research report on Monday, September 25th. One research analyst has rated the stock with a sell rating, four have given a hold rating and fifteen have given a buy rating to the company’s stock. Boston Scientific has an average rating of “Buy” and a consensus price target of $30.97.

In other Boston Scientific news, EVP Michael P. Phalen sold 15,500 shares of Boston Scientific stock in a transaction dated Friday, September 29th. The shares were sold at an average price of $28.72, for a total value of $445,160.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Timothy A. Pratt sold 10,000 shares of Boston Scientific stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $26.04, for a total transaction of $260,400.00. Following the completion of the transaction, the executive vice president now directly owns 154,681 shares of the company’s stock, valued at $4,027,893.24. The disclosure for this sale can be found here. Over the last three months, insiders have sold 424,698 shares of company stock valued at $12,273,553. 0.74% of the stock is currently owned by corporate insiders.

COPYRIGHT VIOLATION WARNING: “Boston Scientific Corporation (BSX) Shares Bought by Nordea Investment Management AB” was posted by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright & trademark legislation. The correct version of this report can be read at https://stocknewstimes.com/2017/12/06/boston-scientific-corporation-bsx-shares-bought-by-nordea-investment-management-ab.html.

Boston Scientific Company Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Institutional Ownership by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply